Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

C.J. Ryan, M. Rosenthal, S. Ng, J. Alumkal, J. Picus, G. Gravis, K. Fizazi, F. Forget, J.P. Machiels, S. Srinivas, M. Zhu, R. Tang, K.S. Oliner, Y.Z. Jiang, E. Loh, S. Dubey, W.R. Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)215-224
JournalClinical Cancer Research
Issue number1
Publication statusPublished - 2013

Cite this